Lenalidomide Krka

Lenalidomide, the active ingredient in Lenalidomide Krka, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma and myelodysplastic syndromes, in adult patients. GNH USA supplies Lenalidomide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: improves progression‑free and overall survival in eligible patients. - Myelodysplastic syndromes (del(5q) cytogenetic abnormality): reduces transfusion dependence and may achieve cytogenetic remission. - Relapsed or refractory multiple myeloma: provides an additional therapeutic option after prior therapies have failed.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to easy bruising. - Diarrhea: loose stools that may be mild to moderate. - Constipation: difficulty passing stools. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Severe thrombocytopenia: dangerously low platelets. - Secondary primary malignancies: emergence of new cancers. - Severe liver injury: marked elevation of hepatic enzymes. - Hypersensitivity reactions: anaphylaxis or severe skin reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters. - Pregnancy contraindication: teratogenic; avoid use in pregnant women and ensure effective contraception. - Thrombosis risk: assess for prior clotting events; consider prophylactic anticoagulation when appropriate. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust dosing in patients with reduced kidney function. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Thalidomide: combined use increases teratogenic and neurotoxic risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): heightened risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., cyclosporine, tacrolimus): may require dose adjustment. - NSAIDs: increased potential for gastrointestinal bleeding. - Live vaccines: attenuated immune response; avoid concurrent administration.